# US 2020/0368257 A1 · Compositions and Methods for the Treatment of Inflammation in Urological Pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368257 A1
- Document ID: US20200368257A1
- Status: Published application
- Kind: A1
- Application number: 16/879,693
- Filed: 2020-05-20
- Published: 2020-11-26
- Earliest claimed: 2019-05-20
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Todd Purves; Francis Hughes
- Web page: https://patentgrep.com/patent/US20200368257A1

## CPC

- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/277: having a ring, e.g. verapamil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compositions and methods for the treatment of inflammation in urological pathologies.

## Claims

### Claim 1

A method of treating inflammation in the bladder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an inflammasome inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammation in the bladder is an acute inflammation or a chronic inflammation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inflammation in the bladder is induced by a danger associated molecular pattern (DAMP) or a pathogen associated molecular pattern (PAMP).

### Claim 4 (depends on 3)

The method of claim 3, wherein the PAMP is a fungus, bacteria, or virus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inflammasome inhibitor is an NLRP1 inflammasome inhibitor, an NLRP3 inflammasome inhibitor, an NLRP6 inflammasome inhibitor, an NLRP7 inflammasome inhibitor, an NLPR9 inflammasome inhibitor, an NLRP12 inflammasome inhibitor, an NLRC4 inflammasome inhibitor, or an AIM2 inflammasome inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inflammasome inhibitor is an NLRP3 inflammasome inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the NLRP3 inflammasome inhibitor is a TXNIP inhibitor, ASC inhibitor, NEK7 inhibitor, Gasdermin D inhibitor, capspase-11 inhibitor, capsase-1 inhibitor, IL-1β inhibitor, IL-18 inhibitor or combinations thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the NLRP3 inflammasome inhibitor is glyburide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is diagnosed with diabetes, urinary tract infection, urinary frequency, fibrosis, bladder outlet obstruction, interstitial cystitis, CP-induced cystitis, depression, anxiety, neuroinflammation, a gynecologic cancer, kidney stones, a pelvic inflammatory disorder, endometriosis, Chron's disease, diverticulitis, lupus, tuberculosis, and combinations thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject had been exposed to chemotherapy, radiation, a catheter, or a urinary stent.

### Claim 12

A method of treating diabetic bladder dysfunction (DBD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inflammasome inhibitor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the inflammasome inhibitor is an NLRP1 inflammasome inhibitor, an NLRP3 inflammasome inhibitor, an NLRP6 inflammasome inhibitor, an NLRP7 inflammasome inhibitor, an NLPR9 inflammasome inhibitor, an NLRP12 inflammasome inhibitor, an NLRC4 inflammasome inhibitor, or an AIM2 inflammasome inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the inflammasome inhibitor is an NLRP3 inflammasome inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the NLRP3 inflammasome inhibitor is a TXNIP inhibitor, ASC inhibitor, NEK7 inhibitor, Gasdermin D inhibitor, capspase-11 inhibitor, capsase-1 inhibitor, IL-1β inhibitor, IL-18 inhibitor or combinations thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein the NLRP3 inflammasome inhibitor is glyburide.

### Claim 17

A method of treating or preventing a condition associated with neuroinflammation in a subject, the method comprising administering a therapeutically effective amount of an inflammasome inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject has been diagnosed with interstitial cystitis, BOO, or DBD.

### Claim 19 (depends on 17)

The method of claim 17, wherein the condition associated with neuroinflammation in a subject is a mood disorder.

### Claim 20 (depends on 17)

The method of claim 17, the method further comprising administering a therapeutically effective amount of an antidepressant agent.
